ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

6 links0 made here, not in the record10 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05328440Treatment of DalpiciclibCombined With Pyrotinib forTrastuzumab-sensitive HER2+Advanced BreastCancer(DAP-Her-02)Henan Cancer HospitalPhase 2 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 16 · ClinicalTrials.gov record · Version of 2026-10-16Version of 2026-10-16CONDITIONSBreast NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSShr-1258 dimaleateEntry “Pyrotinib Maleate”, read by ou…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundDalpiciclib isethionateEntry “Dalpiciclib Isethionate Tablet…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundInetetamabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundFulvestrantIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · Not givenNot given

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Shr-1258 dimaleate

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Pyrotinib Maleate”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Background
Background · 2

All judgments on this study

WhenLinkJudgeDecisionState
Oct 16The record itselfClinicalTrials.gov recordVersion of 2026-10-16Record change
Nov 2Shr-1258 dimaleateClaude Opus 5.5BackgroundCurrent
Nov 2Dalpiciclib isethionateClaude Opus 5.5BackgroundCurrent
Nov 2InetetamabClaude Opus 5.5BackgroundCurrent
Nov 2FulvestrantClaude Opus 5.5Background · partnerCurrent
Nov 2TrastuzumabClaude Opus 5.5Not givenCurrent
Nov 18Shr-1258 dimaleateRule based · role ruleBackgroundAgrees
Nov 18Dalpiciclib isethionateRule based · role ruleBackgroundAgrees
Nov 18InetetamabRule based · role ruleBackgroundAgrees
Nov 18FulvestrantRule based · role ruleBackgroundAgrees
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.